Adamis Pharmaceuticals (ADMP) Announces Tempol Reduces Lung Inflammation in the COVID-19 Challenged Hamster Model

Go back to Adamis Pharmaceuticals (ADMP) Announces Tempol Reduces Lung Inflammation in the COVID-19 Challenged Hamster Model

Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the COVID-19 Challenged Hamster Model

March 15, 2021 9:00 AM EDT

SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") announced today that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with the virus that causes COVID-19 (SARS-CoV-2), resulted in decreased inflammation in the lungs of animals treated with Tempol compared to controls. This is the... More